VRTX Share Price

Open 158.14 Change Price %
High 163.64 1 Day 3.84 2.41
Low 156.53 1 Week 33.96 26.28
Close 163.17 1 Month 29.67 22.22
Volume 3176393 1 Year 69.28 73.79
52 Week High 167.00
52 Week Low 71.46
VRTX Important Levels
Resistance 2 169.76
Resistance 1 167.04
Pivot 161.11
Support 1 159.30
Support 2 156.58
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
ASTI 0.00 0.00%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
More..
NASDAQ USA Top Gainers Stocks
TEAR 3.34 89.77%
SCHS 0.05 66.67%
LOCM 0.09 50.00%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
TOPS 0.26 23.81%
BONT 0.80 17.65%
HAUP 0.07 16.67%
PLUG 2.44 15.09%
More..
NASDAQ USA Top Losers Stocks
DEER 0.00 -100.00%
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
AMCF 0.01 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)

VRTX Technical Analysis 5
As on 21st Jul 2017 VRTX Share Price closed @ 163.17 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 98.69 & Strong Buy for SHORT-TERM with Stoploss of 126.42 we also expect STOCK to react on Following IMPORTANT LEVELS.
VRTX Target for July
1st Target up-side 137.86
2nd Target up-side 144.16
3rd Target up-side 150.46
1st Target down-side 119.88
2nd Target down-side 113.58
3rd Target down-side 107.28
VRTX Other Details
Segment EQ
Market Capital 9959515136.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.vrtx.com
VRTX Address
VRTX
50 Northern Avenue
Boston, MA 02210
United States
Phone: 617-341-6100
Interactive Technical Analysis Chart Vertex Pharmaceuticals Incorporated ( VRTX NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Vertex Pharmaceuticals Incorporated
VRTX Business Profile
Vertex Pharmaceuticals Incorporated (Vertex) is in the business of discovering, developing, manufacturing and commercializing small molecule drugs for the treatment of serious diseases. The Company�s two products are INCIVEK (telaprevir), which is approved for the treatment of patients with genotype 1 hepatitis C virus (HCV), infection, and KALYDECO (ivacaftor), which is approved in the United States for the treatment of patients six years of age and older with cystic fibrosis (CF), who have at least one copy of the G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR), gene. The Company has ongoing clinical programs involving drug candidates intended for the treatment of HCV infection, CF, rheumatoid arthritis, influenza and epilepsy. INCIVEK (telaprevir) achieved initial commercial acceptance following its approval in May 2011. It started marketing KALYDECO in the United States in January 2012.